NewBiotics Inc.
This article was originally published in Start Up
Executive Summary
NewBiotics Inc. is harnessing the power of the thymidylate synthase (TS) enzyme. TS, which is involved in DNA synthesis, normally is overexpressed in tumor cells, leading to resistance to chemotherapeutic agents. NewBiotics is designing prodrugs that are activated by TS inside the cell, leading to programmed cell death instead of chemoprotection.